Peter S. Conti

University of Southern California — United States

Physics and Astronomy · Physical Sciences

79h-index23.3kcitations780works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Stellar, planetary, and galactic studies(318), Astronomy and Astrophysical Research(246), Astrophysics and Star Formation Studies(138), Astronomical Observations and Instrumentation(132), Radiopharmaceutical Chemistry and Applications(103)

Publications780 total

2401P Combined treatment with radium-223 (RAD) and enzalutamide (ENZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Insights from the global REASSURE study
Annals of Oncology·2025
Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study.
Journal of Clinical Oncology·2025
Clinical utility of [ <sup>18</sup> F]fluoroestradiol (FES) PET/CT to guide second-line treatment decision in patients with ER-positive HER2-negative metastatic breast cancer progressing on first-line endocrine therapy.
Journal of Clinical Oncology·2025
Oral Inhaled Cromolyn for Mild-to-Moderate Amyotrophic Lateral Sclerosis: A Randomized, Open Label Phase 2a Study
2025Open Access
Clinical trials in cancer theranostics with potential near-term impact on clinical practice
British Journal of Radiology·2025· 1 cited
Abstract C160: Baseline characteristics, safety, and efficacy of Radium-223 in metastatic castration resistant prostate cancer by race: Insights from the REASSURE US subset
Cancer Epidemiology Biomarkers & Prevention·2024
Unresectable Metastatic Solid Pseudopapillary Pancreatic Neoplasm Treated With Liver Transplantation
ACG Case Reports Journal·2024· 2 citedOpen Access
Comparing patient profiles and treatment outcomes with radium-223 (<sup>223</sup>Ra) in real-world settings: Academic vs. community practice in the US—Insights from the REASSURE study.
Journal of Clinical Oncology·2024
Safety outcomes in patients with metastatic castration-resistant prostate cancer treated with radium-223 following external beam radiation therapy: REASSURE US subset.
Journal of Clinical Oncology·2024
S3649 Unresectable Metastatic Solid Pseudopapillary Pancreatic Neoplasm Treated With Liver Transplantation: A Case Report
The American Journal of Gastroenterology·2023
Real-world safety and effectiveness of radium-223 (<sup>223</sup>Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.
Journal of Clinical Oncology·2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
EClinicalMedicine·2023· 34 citedOpen Access
Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)·2023Open Access
Data from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
Supplementary Methods from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
Supplementary Methods from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
Supplementary Tables 1 - 2 from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
Supplementary Tables 1 - 2 from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
Supplementary Figures 1 - 9 from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
Data from Monoclonal Antibody against Cell Surface GRP78 as a Novel Agent in Suppressing PI3K/AKT Signaling, Tumor Growth, and Metastasis
2023Open Access
page 1 of 39Next →

Frequent Co-authors

James R. Bading(11), Xiaohong Chen(8), Ryan J. Park(7), Michel Tohme(6), Zibo Li(6), Hossein Jadvar(4), Lingyun Ji(3), Susan Groshen(3), Tanya B. Dorff(3), Rex Moats(3), Mian M. Alauddin(3), Anthony H. Shahinian(3), Yingping Hou(3), William D. Vacca(3), Bhushan Desai(3), Sebastian Brandhorst(2), Min Wei(2), Valter D. Longo(2), M. M. Hanson(2), Vazgen Khankaldyyan(2)